973 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
PFE Pfizer, Inc. $43.01 $252.13B Downtrend
Article Searches
Pharma Industry Outlook: Fundamentals Remain Strong http://www.zacks.com/commentary/86599/pharma-industry-outlook-fundamentals-remain-strong?cid=CS-ZC--86599 Jul 22, 2016 - Pharma Industry Outlook: Fundamentals Remain Strong
J&J (JNJ) Stock Gains on Q2 Earnings and Improved Outlook http://www.zacks.com/stock/news/223958/jj-jnj-stock-gains-on-q2-earnings-and-improved-outlook?cid=CS-ZC-FT-223958 Jul 19, 2016 - Johnson & Johnson's (JNJ) shares were up in pre-market trading with the company beating on all fronts and raising its guidance for 2016.
Roche's Gazyva Fails in Phase III B-cell Lymphoma Study http://www.zacks.com/stock/news/223876/roches-gazyva-fails-in-phase-iii-b-cell-lymphoma-study?cid=CS-ZC-FT-223876 Jul 18, 2016 - Roche Holding AG (RHHBY) announced disappointing results from the phase III study on Gazyva.
Dow 30 Stock Roundup: JPM Q2 Impresses, Orders for Boeing & United Technologies http://www.zacks.com/stock/news/223817/dow-30-stock-roundup-jpm-q2-impresses-orders-for-boeing-united-technologies?cid=CS-ZC-FT-223817 Jul 18, 2016 - The Dow notched up heavy gains during an eventful week, boosted by multiple factors.
Ultragenyx (RARE) Reports Positive Phase III rhGUS Data http://www.zacks.com/stock/news/223590/ultragenyx-rare-reports-positive-phase-iii-rhgus-data?cid=CS-ZC-FT-223590 Jul 15, 2016 - Ultragenyx (RARE) announced top-line data from a pivotal phase III study on rhGUS for the treatment of mucopolysaccharidosis 7.
Pfizer Publishes Final Data from Atopic Dermatitis Studies http://www.zacks.com/stock/news/223503/pfizer-publishes-final-data-from-atopic-dermatitis-studies?cid=CS-ZC-FT-223503 Jul 14, 2016 - Pfizer (PFE) announced findings from two pivotal phase III studies on crisaborole for the treatment of patients with mild-to-moderate atopic dermatitis.
Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13 http://www.zacks.com/stock/news/223329/pfizer-pfe-gets-fda-nod-for-label-expansion-of-prevnar-13?cid=CS-ZC-FT-223329 Jul 13, 2016 - Pfizer Inc. (PFE) announced that the FDA has approved a label expansion of vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
Sucampo to Stop Developing Cobiprostone for Oral Mucositis http://www.zacks.com/stock/news/223221/sucampo-to-stop-developing-cobiprostone-for-oral-mucositis?cid=CS-ZC-FT-223221 Jul 13, 2016 - Sucampo Pharmaceuticals, Inc. (SCMP) announced that it will discontinue the development of its pipeline candidate, cobiprostone.
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod http://www.zacks.com/stock/news/223218/shires-shpg-dry-eye-disease-drug-xiidra-gets-fda-nod?cid=CS-ZC-FT-223218 Jul 13, 2016 - Shire plc (SHPG) received a major boost when the FDA approved its ophthalmology drug Xiidra for the treatment of the signs and symptoms of dry eye disease in adults.
Don't Make It Complicated, Own Drug Stocks http://www.zacks.com/commentary/83063/dont-make-it-complicated-own-drug-stocks?cid=CS-ZC--83063 Jun 14, 2016 - Don't Make It Complicated, Own Drug Stocks

Pages: 1...909192939495969798

<<<Page 95>